Solid Biosciences (SLDB) Capital Expenditures (2017 - 2026)

Solid Biosciences has disclosed Capital Expenditures across 10 years of filings, most recently posting $25000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $25000.0, down 68.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$9000.0 (up 86.96% YoY), and the FY2025 annual result was $46000.0, changed N/A from the prior year.
• Capital Expenditures came in at $25000.0 for Q1 2026 at Solid Biosciences, up from -$283000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.5 million in Q4 2023 to a low of -$383000.0 in Q3 2022.
• The 5-year median for Capital Expenditures is $25000.0 (2026), against an average of $124294.1.
• Across the five-year window, Capital Expenditures soared 2700.0% in 2022 and tumbled 1187.5% in 2025, its largest moves.
• Solid Biosciences' Capital Expenditures stood at $310000.0 in 2022, then soared by 388.71% to $1.5 million in 2023, then plunged by 102.38% to -$36000.0 in 2024, then plunged by 686.11% to -$283000.0 in 2025, then jumped by 108.83% to $25000.0 in 2026.
• The last three Capital Expenditures figures came in at $25000.0 (Q1 2026), -$283000.0 (Q4 2025), and -$174000.0 (Q3 2025), per Business Quant data.